Global Oncology Biosimilars Market Research Report 2021

1 Oncology Biosimilars Market Overview

• 1.1 Product Overview and Scope of Oncology Biosimilars
• 1.2 Oncology Biosimilars Segment by Type
  • 1.2.1 Global Oncology Biosimilars Sales Growth Rate Comparison by Type (2021-2027)
  • 1.2.2 Monoclonal Antibody
  • 1.2.3 Hematopoietic Agents
  • 1.2.4 G-CSF
  • 1.2.5 Others
• 1.3 Oncology Biosimilars Segment by Application
  • 1.3.1 Oncology Biosimilars Sales Comparison by Application: (2021-2027)
  • 1.3.2 Retail Pharmacies
  • 1.3.3 Hospital Pharmacy
  • 1.3.4 Online Pharmacy
• 1.4 Global Oncology Biosimilars Market Size Estimates and Forecasts
  • 1.4.1 Global Oncology Biosimilars Revenue 2016-2027
  • 1.4.2 Global Oncology Biosimilars Sales 2016-2027
  • 1.4.3 Oncology Biosimilars Market Size by Region: 2016 Versus 2021 Versus 2027

2 Oncology Biosimilars Market Competition by Manufacturers

• 2.1 Global Oncology Biosimilars Sales Market Share by Manufacturers (2016-2021)
• 2.2 Global Oncology Biosimilars Revenue Market Share by Manufacturers (2016-2021)
• 2.3 Global Oncology Biosimilars Average Price by Manufacturers (2016-2021)
• 2.4 Manufacturers Oncology Biosimilars Manufacturing Sites, Area Served, Product Type
• 2.5 Oncology Biosimilars Market Competitive Situation and Trends
  • 2.5.1 Oncology Biosimilars Market Concentration Rate
  • 2.5.2 The Global Top 5 and Top 10 Largest Oncology Biosimilars Players Market Share by Revenue
  • 2.5.3 Global Oncology Biosimilars Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
• 2.6 Manufacturers Mergers & Acquisitions, Expansion Plans

3 Oncology Biosimilars Retrospective Market Scenario by Region

• 3.1 Global Oncology Biosimilars Retrospective Market Scenario in Revenue by Region: 2016-2021
• 3.2 Global Oncology Biosimilars Retrospective Market Scenario in Sales by Region: 2016-2021
• 3.3 North America Oncology Biosimilars Market Facts & Figures by Country
  • 3.3.1 North America Oncology Biosimilars Sales by Country
  • 3.3.2 North America Oncology Biosimilars Revenue by Country
  • 3.3.3 U.S.
  • 3.3.4 Canada
• 3.4 Europe Oncology Biosimilars Market Facts & Figures by Country
  • 3.4.1 Europe Oncology Biosimilars Sales by Country
  • 3.4.2 Europe Oncology Biosimilars Revenue by Country
  • 3.4.3 Germany
  • 3.4.4 France
  • 3.4.5 U.K.
  • 3.4.6 Italy
  • 3.4.7 Russia
• 3.5 Asia Pacific Oncology Biosimilars Market Facts & Figures by Region
  • 3.5.1 Asia Pacific Oncology Biosimilars Sales by Region
  • 3.5.2 Asia Pacific Oncology Biosimilars Revenue by Region
  • 3.5.3 China
  • 3.5.4 Japan
  • 3.5.5 South Korea
  • 3.5.6 India
  • 3.5.7 Australia
  • 3.5.8 Taiwan
  • 3.5.9 Indonesia
  • 3.5.10 Thailand
  • 3.5.11 Malaysia
  • 3.5.12 Philippines
  • 3.5.13 Vietnam
• 3.6 Latin America Oncology Biosimilars Market Facts & Figures by Country
  • 3.6.1 Latin America Oncology Biosimilars Sales by Country
  • 3.6.2 Latin America Oncology Biosimilars Revenue by Country
  • 3.6.3 Mexico
  • 3.6.4 Brazil
  • 3.6.5 Argentina
• 3.7 Middle East and Africa Oncology Biosimilars Market Facts & Figures by Country
  • 3.7.1 Middle East and Africa Oncology Biosimilars Sales by Country
  • 3.7.2 Middle East and Africa Oncology Biosimilars Revenue by Country
  • 3.7.3 Turkey
  • 3.7.4 Saudi Arabia
  • 3.7.5 U.A.E

4 Global Oncology Biosimilars Historic Market Analysis by Type

• 4.1 Global Oncology Biosimilars Sales Market Share by Type (2016-2021)
• 4.2 Global Oncology Biosimilars Revenue Market Share by Type (2016-2021)
• 4.3 Global Oncology Biosimilars Price by Type (2016-2021)

5 Global Oncology Biosimilars Historic Market Analysis by Application

• 5.1 Global Oncology Biosimilars Sales Market Share by Application (2016-2021)
• 5.2 Global Oncology Biosimilars Revenue Market Share by Application (2016-2021)
• 5.3 Global Oncology Biosimilars Price by Application (2016-2021)

6 Key Companies Profiled

• 6.1 Celltrion
  • 6.1.1 Celltrion Corporation Information
  • 6.1.2 Celltrion Description and Business Overview
  • 6.1.3 Celltrion Oncology Biosimilars Sales, Revenue and Gross Margin (2016-2021)
  • 6.1.4 Celltrion Product Portfolio
  • 6.1.5 Celltrion Recent Developments/Updates
• 6.2 Biocon
  • 6.2.1 Biocon Corporation Information
  • 6.2.2 Biocon Description and Business Overview
  • 6.2.3 Biocon Oncology Biosimilars Sales, Revenue and Gross Margin (2016-2021)
  • 6.2.4 Biocon Product Portfolio
  • 6.2.5 Biocon Recent Developments/Updates
• 6.3 Dr. Reddy’s Laboratories
  • 6.3.1 Dr. Reddy’s Laboratories Corporation Information
  • 6.3.2 Dr. Reddy’s Laboratories Description and Business Overview
  • 6.3.3 Dr. Reddy’s Laboratories Oncology Biosimilars Sales, Revenue and Gross Margin (2016-2021)
  • 6.3.4 Dr. Reddy’s Laboratories Product Portfolio
  • 6.3.5 Dr. Reddy’s Laboratories Recent Developments/Updates
• 6.4 STADA Arzneimittel AG
  • 6.4.1 STADA Arzneimittel AG Corporation Information
  • 6.4.2 STADA Arzneimittel AG Description and Business Overview
  • 6.4.3 STADA Arzneimittel AG Oncology Biosimilars Sales, Revenue and Gross Margin (2016-2021)
  • 6.4.4 STADA Arzneimittel AG Product Portfolio
  • 6.4.5 STADA Arzneimittel AG Recent Developments/Updates
• 6.5 Intas Pharmaceuticals
  • 6.5.1 Intas Pharmaceuticals Corporation Information
  • 6.5.2 Intas Pharmaceuticals Description and Business Overview
  • 6.5.3 Intas Pharmaceuticals Oncology Biosimilars Sales, Revenue and Gross Margin (2016-2021)
  • 6.5.4 Intas Pharmaceuticals Product Portfolio
  • 6.5.5 Intas Pharmaceuticals Recent Developments/Updates
• 6.6 Pfizer
  • 6.6.1 Pfizer Corporation Information
  • 6.6.2 Pfizer Description and Business Overview
  • 6.6.3 Pfizer Oncology Biosimilars Sales, Revenue and Gross Margin (2016-2021)
  • 6.6.4 Pfizer Product Portfolio
  • 6.6.5 Pfizer Recent Developments/Updates
• 6.7 Sandoz International
  • 6.6.1 Sandoz International Corporation Information
  • 6.6.2 Sandoz International Description and Business Overview
  • 6.6.3 Sandoz International Oncology Biosimilars Sales, Revenue and Gross Margin (2016-2021)
  • 6.4.4 Sandoz International Product Portfolio
  • 6.7.5 Sandoz International Recent Developments/Updates
• 6.8 Teva Pharmaceutical Industries Ltd
  • 6.8.1 Teva Pharmaceutical Industries Ltd Corporation Information
  • 6.8.2 Teva Pharmaceutical Industries Ltd Description and Business Overview
  • 6.8.3 Teva Pharmaceutical Industries Ltd Oncology Biosimilars Sales, Revenue and Gross Margin (2016-2021)
  • 6.8.4 Teva Pharmaceutical Industries Ltd Product Portfolio
  • 6.8.5 Teva Pharmaceutical Industries Ltd Recent Developments/Updates
• 6.9 Apotex
  • 6.9.1 Apotex Corporation Information
  • 6.9.2 Apotex Description and Business Overview
  • 6.9.3 Apotex Oncology Biosimilars Sales, Revenue and Gross Margin (2016-2021)
  • 6.9.4 Apotex Product Portfolio
  • 6.9.5 Apotex Recent Developments/Updates
• 6.10 BIOCAD
  • 6.10.1 BIOCAD Corporation Information
  • 6.10.2 BIOCAD Description and Business Overview
  • 6.10.3 BIOCAD Oncology Biosimilars Sales, Revenue and Gross Margin (2016-2021)
  • 6.10.4 BIOCAD Product Portfolio
  • 6.10.5 BIOCAD Recent Developments/Updates

7 Oncology Biosimilars Manufacturing Cost Analysis

• 7.1 Oncology Biosimilars Key Raw Materials Analysis
  • 7.1.1 Key Raw Materials
  • 7.1.2 Key Suppliers of Raw Materials
• 7.2 Proportion of Manufacturing Cost Structure
• 7.3 Manufacturing Process Analysis of Oncology Biosimilars
• 7.4 Oncology Biosimilars Industrial Chain Analysis

8 Marketing Channel, Distributors and Customers

• 8.1 Marketing Channel
• 8.2 Oncology Biosimilars Distributors List
• 8.3 Oncology Biosimilars Customers

9 Oncology Biosimilars Market Dynamics

• 9.1 Oncology Biosimilars Industry Trends
• 9.2 Oncology Biosimilars Growth Drivers
• 9.3 Oncology Biosimilars Market Challenges
• 9.4 Oncology Biosimilars Market Restraints

10 Global Market Forecast

• 10.1 Oncology Biosimilars Market Estimates and Projections by Type
  • 10.1.1 Global Forecasted Sales of Oncology Biosimilars by Type (2022-2027)
  • 10.1.2 Global Forecasted Revenue of Oncology Biosimilars by Type (2022-2027)
• 10.2 Oncology Biosimilars Market Estimates and Projections by Application
  • 10.2.1 Global Forecasted Sales of Oncology Biosimilars by Application (2022-2027)
  • 10.2.2 Global Forecasted Revenue of Oncology Biosimilars by Application (2022-2027)
• 10.3 Oncology Biosimilars Market Estimates and Projections by Region
  • 10.3.1 Global Forecasted Sales of Oncology Biosimilars by Region (2022-2027)
  • 10.3.2 Global Forecasted Revenue of Oncology Biosimilars by Region (2022-2027)

11 Research Finding and Conclusion

12 Methodology and Data Source

• 12.1 Methodology/Research Approach
  • 12.1.1 Research Programs/Design
  • 12.1.2 Market Size Estimation
  • 12.1.3 Market Breakdown and Data Triangulation
• 12.2 Data Source
  • 12.2.1 Secondary Sources
  • 12.2.2 Primary Sources
• 12.3 Author List